Edwards Lifesciences Corporation logo
EWEdwards Lifesciences Corporation

Enterprise Value (EV): $49.96B

The enterprise value (EV) is $49.96B as of Sunday, June 28, 2026.

EW Enterprise Value (EV) Metrics

ENTERPRISE VALUE (EV)

$49.96B

Enterprise Value Calculation

Market Cap

$52.27B

+

Total Debt

$622.80M

Cash

$2.94B

=

Enterprise Value

$49.96B

EV-Based Valuation Multiples

Why use EV instead of Market Cap?

  • EV accounts for debt - an acquirer must pay or assume it
  • EV deducts cash - the acquirer effectively receives it
  • EV enables fair comparison of companies with different capital structures
  • EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Edwards Lifesciences Corporation (EW)?
The enterprise value (EV) for EW stock is $49.96B.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA
15,800 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian